论文部分内容阅读
目的探讨分析奥沙利铂联合替吉奥一线治疗老年晚期胃癌的临床研究应用效果。方法选取2014年8月至2015年8月老年晚期胃癌患者79例作为研究对象,按照治疗方式的不同分为观察组和对照组。对照组采用奥沙利铂联合卡培他滨治疗,观察组给予奥沙利铂联合替吉奥治疗,对比两组患者的治疗效果。结果治疗后观察组总有效率为82.50%,对照组为79.49%,差异未见统计学意义(P>0.05)。两组患者白细胞、中性粒细胞、血小板减少及肝、肾功能异常情况比较差异未见统计学意义(P>0.05),但观察组消化道不良反应发生率明显低于对照组(P<0.05)。结论奥沙利铂联合替吉奥治疗效果确切,安全可靠,可减少晚期胃癌患者的消化道不良反应发生率,值得临床推广。
Objective To investigate the clinical effect of oxaliplatin combined with tiagacin in the treatment of elderly patients with advanced gastric cancer. Methods A total of 79 elderly patients with advanced gastric cancer from August 2014 to August 2015 were selected as study subjects and divided into observation group and control group according to different treatment methods. The control group was treated with oxaliplatin combined with capecitabine. The observation group was treated with oxaliplatin combined with tirofiban, and the therapeutic effect was compared between the two groups. Results After treatment, the total effective rate was 82.50% in the observation group and 79.49% in the control group, with no significant difference (P> 0.05). There were no significant differences in the leukocyte, neutrophil, thrombocytopenia and abnormal liver and kidney function between the two groups (P> 0.05), but the incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05 ). Conclusion The combination of oxaliplatin and tirofiban is safe and reliable, which can reduce the incidence of gastrointestinal adverse reactions in patients with advanced gastric cancer and is worthy of clinical promotion.